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Background: Depression and anxiety are common in cancer and antidepressants (AD) 
are an efficacious treatment. The relationship between AD adherence and mortality in 
cancer is unclear. This study aimed to evaluate the association between adherence to AD 
and all-cause mortality in a population-based cohort of patients with cancer. 
Methods: We conducted a four-year historical prospective cohort study including 42,075 
patients with cancer who purchased AD at least once during the study period. Adherence 
to AD was modeled as non-adherence (<20%), poor (20%-50%), moderate (50% - 80%), 
and good (>80%) adherence. We conducted multivariable survival analyses adjusted for 
demographic and clinical variables that may affect mortality.  
Results: During 1,051,489 person years at risk follow-up, the adjusted hazard ratios (HR) 
for mortality were 0.89 [95%CI: 0.83–0.95], 0.77 [95%CI: 0.66-0.72] and 0.80 [95%CI: 
0.76–0.85] for the poor, moderate and good adherence groups, respectively, compared to 
the non-adherent group. Analysis of the entire sample and a subgroup with depression, 
for cancer subtypes revealed similar patterns for breast, colon, lung and prostate cancers, 
but not for melanoma patients. Multivariate predictors of premature mortality included 
male gender (HR 1.48 [95%CI: 1.42–1.55]), current/past smoking status (HR 1.1, 
[95%CI: 1.04-1.15], p <0.0001), low socioeconomic status (HR 1.1, [95%CI: 1.03-1.17], 
p<0.0001) and more physical comorbidities.   
Conclusions: The present study is the first to demonstrate that higher adherence to AD is 
associated with a decrease of all-cause mortality in a large nationwide cohort of cancer 
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Prevalence rates of major depression among cancer patients are four times higher 
than the general population (Bortolato et al., 2017; Ostuzzi, Matcham, Dauchy, Barbui, & 
Hotopf, 2015) and up to a quarter of oncologic patients have clinically significant 
depressive and anxiety symptoms (Mitchell et al., 2011; Pirl, 2004). These rates increase 
in patients with poorer prognosis (Benton, Staab, & Evans, 2007) and in end stages of the 
disease (Lo et al., 2010). Depression in cancer patients has been associated not only with 
a substantially reduced quality of life (Grassi et al., 1996), greater physical distress (Chen 
& Chang, 2004) and prolonged hospital stays (Prieto et al., 2002), but also with poorer 
adherence to the cytotoxic medications (Colleoni, Mandala, Peruzzotti, Robertson, 
Bredart, & Goldhirsch, 2000), that in turn may aggravate the chance for survival. Most 
notably, co-morbid depression in patients with cancer was compellingly established as an 
independent risk factor for suicide (Chochinov, Wilson, Enns, & Lander, 1998) as well as 
rapid cancer progression and mortality (Lloyd-Williams, Shiels, Taylor, & Dennis, 2009; 
Pinquart & Duberstein, 2010; Satin, Linden, & Phillips, 2009). A recent large population-
based study in England indicated a 2-4 fold elevated risk of suicide in patients with 
certain cancers and that suicide risk was highest in the first 6 months following cancer 
diagnosis (Henson, Brock, Charnock, Wickramasinghe, Will, & Pitman, 2018).  
To-date, only scarce and methodologically-limited reports yielding contradictory 
data are available on this issue (Ostuzzi et al.,2015; Ostuzzi, Matcham, Dauchy, Barbui, 
& Hotopf, 2018). There have been three recent systematic reviews of pharmacologic 
treatment for depression in patients with cancer (Ng, Boks, Zainal, & de Wit, 2011; 
Rodin, Lloyd, Katz, Green, Mackay, & Wong, 2007; Williams & Dale, 2006), which 
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provided mixed evidence for the effectiveness of antidepressant drugs (AD) for 
depression and none evaluated their effect on mortality. In a cohort of 17,883 patients 
with either colorectal cancer or glioma, there was no significant mortality reduction in 
those who used tricyclic antidepressants (TCA) (Walker, Grainge, Bates, & Card, 2012). 
A similar finding was found in a study examining the use vs. non-use of any AD in a 
sample of 1,306 women with breast cancer (Chubak, Buist, Boudreau, Rossing, Lumley, 
& Weiss, 2008). In contrast, in another cohort of 3,058 breast cancer patients, there was a 
50% increased risk of all-cause mortality in those who used AD (Wernli, Hampton, 
Trentham-Dietz, & Newcomb, 2011). Moreover, a randomized controlled trial of 
sertraline vs. placebo was suspended after the pre-planned interim analysis of the first 
189 participants indicated that patients who received sertraline had a significantly shorter 
survival time than the placebo group (adjusted hazard ratio 1.62) (Stockler et al., 2007).       
Depression and anxiety are treatable in medically-ill patients (Ramasubbu et al., 
2012), but there is still a lack of a pharmacological treatment algorithm for the use of AD 
in patients with cancer (Okamura et al., 2008; Reich, 2008). This task may be challenging 
not only due to the dearth of consistent knowledge regarding the effect of AD on the 
mortality of these patients, but also because present analyses have not taken into account 
the actual adherence of the patients to AD. 
Whereas AD are widely prescribed internationally (Beck et al., 2005; Kivimaki et 
al., 2007), low adherence is commonly reported among AD users, with or without cancer. 
A recent case-control study comparing AD adherence among 1142 women with breast 
cancer and pre-existing depression and 1142 matched non-cancer patients with pre-
existing depression revealed similar adherence (70%) for both groups (Chou, Winn, 
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Rosenstein, & Dusetzina, 2017). Wider-scale pharmacoepidemiological studies showed 
similar rates of adherence in non-cancer patients with depression and anxiety. In a report 
of an antidepressant compliance program including 13,128 patients, rates of partial or full 
non-adherence were 75%, dropping later to 40% of days without dispensed AD being 
used (Bambauer et al., 2006).  
Patient adherence rates to AD reflect the actual longitudinal consumption of AD, 
and are measured as a continuous variable, rather than dichotomous use or non-use which 
is far less informative. Previous nationwide cohort studies have found a beneficial effect 
of good adherence to AD for reducing premature mortality in the general population 
(Krivoy et al., 2016), cardiovascular patients (Krivoy et al., 2015), Parkinson Disease 
(Shoval et al., 2017) and stroke patients (Krivoy et al., 2017). To the best of our 
knowledge, no previous study has investigated the association between AD adherence 
and mortality in people with cancer. Given this pertinent gap, we conducted a nationwide 
cohort study to investigate whether higher AD adherence was associated with lower 
mortality in the patient population with cancer. Our secondary objective was to evaluate 
mortality among different types of cancer as function of AD adherence.  
 
METHODS 
We used the nationwide database of Clalit Health Services (CHS), described in detail 
previously(Krivoy et al.,2016). Briefly, this computerized database utilizes data from the 
integrated medical records of the largest health provider in Israel, which covers over 4 
million patients across the lifespan, equating to approximately 53% of the population. 
Health provision in Israel is mandatory for each resident and service users have incentive 
to use the public services due to subsides and low cost of medical services.    
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Population and study period 
We retrospectively analyzed the entire CHS patient population during the study period 
(1.1.2008-1.1.2012) at all ages (N=4,056,700). We included all patients with at least one 
prescription for an AD during the study period and a clinical diagnosis of Malignant 
Neoplasms – ICD 10 code C (N=55,306). All Food and Drug Administration (FDA) 
approved AD were included based on the WHO Anatomical Therapeutic Chemical 
(ATC) code N06A. In the final analyses we included only AD users, namely patients who 
purchased at least one prescription (N=42,075). Access to the data warehouse and the 
analyses were approved for this study by the CHS Review Board. 
 
  





A record of all-cause mortality was the primary outcome during the four-year study 
period, captured from linked data produced by the Ministry for Interior Affairs. Patients 
were followed-up from the entry to the study (i.e. prescription of AD) until death or the 
end of the study period. 
 
Main predictor 
Adherence to antidepressants  
The adherence measure was modeled on the basis of the concept of medication 
possession ratio (data from CHS-owned pharmacies) with the addition of physician 
prescription data (derived from EMR) in accordance with previous research (Krivoy et 
al., 2015; Krivoy et al., 2016; Krivoy et al., 2017; Shoval et al., 2017; Singer et al.,  
2012). Only less than 3% of CHS patients get their prescriptions filled in a non-CHS 
owned pharmacies. Study participation duration was calculated as the continuous period 
between the first and the last prescribed AD. Adherence was defined as the period of AD 
purchased prescriptions (months), during follow-up, divided by study participation 
duration (months). Thus it reflects adherence over the period for which AD were known 
to be prescribed (and therefore indicated). Adherence (medication possession ratio) was 
calculated across all AD used. Switching between different AD compounds was not taken 
into account, and was considered as continuous use of AD. 
𝐴𝑑ℎ𝑒𝑟𝑒𝑛𝑐𝑒 (%) =
Duration of 𝐩𝐮𝐫𝐜𝐡𝐚𝐬𝐞𝐝 AD prescriptions (Months)
Duration of continous 𝐩𝐫𝐞𝐬𝐜𝐫𝐢𝐛𝐞𝐝 AD (Months)
𝑋 100 
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Adherence is reported as a percentage score for each patient. Similarly to previous 
literature (Krivoy et al., 2015; Krivoy et al., 2016; Krivoy et al., 2017; Shoval et 
al.,2017), patients with adherence below 20% were considered non-adherent, those with 
20%-50% adherence were considered poorly adherent, those with 50%-80% were 
considered to have a moderate adherence and patients with adherence above 80% were 
considered to have good adherence. In accordance with previous research, we did not 
model adherence as a continuous variable, since our previous study demonstrated no 
superiority when considering adherence as a continuous versus the categorical variables 
described here (Krivoy et al., 2016).  
 
Covariates  
We collected the following socio-demographic and clinical variables at study entry: age 
(categorized into 0-18, 18-24, 24-40, 40-64, 65-74, 75-84, 85+ years), gender, 
socioeconomic status and self-reported smoking status (categorized as those who never 
smoked and those who smoked in the past or present). We extracted all available data on 
physical comorbidities (ICD-10 diagnoses). Based on these data, we calculated the 
Charlson Comorbidity Index (CCI), the most widely used clinical index for the 
evaluation of comorbidities. The CCI weighs twenty chronic conditions as predictors of 
1-year relative risk of death, and scores between 1 to 20 (Charlson, Pompei, Ales, & 
MacKenzie, 1987). Additionally, it was recorded whether an AD was prescribed at study 
entry or during the study period. We were also able to flag out several sub-populations 
with distinct type of malignancies: breast, lung, colon, prostate, and melanoma. 
  




Statistical analysis was conducted using SPSS version 22 (IBM Corporation, Armonk, 
New York). We performed descriptive statistics of socio-demographics, co-morbidities, 
and adherence levels across the total study population as well as across four adherence 
level groups (<20%, 20%-50%, 50%-80% and >80%). We used univariate associations 
(logistic regression and Kaplan Meier log rank) to assess the association between socio-
demographics and clinical covariates and those who died or stayed alive during the study 
period. We used the multivariable Cox proportional hazard regression model to assess the 
adjusted association between risk of death and adherence level of AD medication 
controlling for confounders that were found to be significant in the univariate analysis 
[age (as a stratified variable), gender, physical co-morbidities modeled as CCI, smoking 
status and socio-economic status]. We tested the assumptions of the proportional hazard 
model using log (-log) plots. Although the database was lacking indication for AD 
prescription, we performed a sensitivity analysis, using the above methodology on a 
subpopulation within the cohort with a diagnosis of Major Depressive disorder (ICD10 
codes: F.32-F.33). Finally, another sensitivity analysis was performed to test patients who 
were prescribed AD only during study period (“new users”) compared to those who prior 
to their cancer diagnosis were being treated with AD for pre-existing depression. Hazard 
ratios (HR) and their 95% confidence interval (CI) are reported. Significance was 









Population characteristics and mortality rates are shown in Table 1. Across the 42,075 
people with cancer, the majority were women (64.7%) and 97% were above 40 years old. 
Most of the sample was native Israeli (88.5%). Unadjusted Mortality rates were higher 
for men than women (25.5% vs. 16.2%, respectively, p<0.0001) and those with higher 
CCI scores were more likely to die during the study period (28.8% on CCI >5 vs. 15.4% 
and 16.7% on CCI 3-4 and 0-2, respectively, p<0.0001 for all comparisons). Total 
number of person years at risk followed-up was 1,051,489. Mean follow up time was 
25±15.9 months (range 1–47 months, median 25 months). Mean follow-up time of 




Thirty seven percent of the study sample discontinued AD within a month after the first 
prescription (i.e. they claimed only a single prescription) and 68.8% of the study sample 
discontinued the drug after less than 6 months. Adherence distribution and variables 
across adherence levels are shown in Table 2. The U-shaped adherence distribution 
indicated that 28.9% of AD users were non-adherent (n=12,092), 16.2% had poor 








Unadjusted analyses (Table 2) show that those with non-adherence had the lowest 
mortality rate (16.3%) compared to the mortality rate of those with poor adherence 
(19.1%), moderate adherence (19.8%) or good adherence (21.9%; p<0.001 for all). These 
statistically significant differences were corroborated by a univariate Kaplan-Meier 
model (Log-rank Mantel-Cox X2=17.5, p=0.001). Older age adults (>65 years) were 
more likely to have good adherence than being non-adherent (40.8% vs. 25.6% 
respectively, p<0.001, see Table 2). Furthermore, there were more severely physically-ill 
patients (CCI>5) in the good adherence group compared to the non-adherence group 
(40.3% vs. 27% respectively, p<0.001).  
 
Multivariable analysis 
The Cox proportional hazards model included mortality as the main outcome and 
variables significantly associated with mortality in the univariate analyses as covariates. 
Adjusted associations between adherence to the aggregate measure of AD and mortality 
appear in Figure 1. We analyzed association between adherence level and mortality using 
Cox Hazard model, while adjusting for age, gender, smoking status, socioeconomic status 
and physical co-morbidities. In analysis of the full sample with malignant neoplasm, the 
lowest HR for mortality was 0.77 [95%Confidence interval (CI): 0.66-0.72] at the level 
of 50%-80% adherence, compared to adherence below 20%. All levels of adherence 
above 20% were associated with significantly reduced HR for mortality (20%-50% 
adherence with HR 0.89 [95%CI: 0.83–0.95] and >80% adherence with HR 0.8 [95%CI: 
0.76–0.85]).  
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The adjusted HR for mortality among men was 1.48 [95%CI: 1.42–1.55] compared to 
women. Other significant predictors of mortality were age (40-64: HR 0.21 [95%CI: 0.2-
0.23], 65-74: HR 0.31 [95%CI: 0.29-0.34] and 75-84 HR 0.51 [95%CI: 0.48-0.54] 
relative to age 85+, p<0.001 for all), current or past smoking status (HR 1.1, [95%CI: 
1.04-1.15], p <0.0001), low socioeconomic status (HR 1.1, [95%CI: 1.03-1.17], 
p<0.0001) compared to high socioeconomic status, and physical chronic comorbidity 
measured by CCI, with HR 0.59, [95%CI: 0.56-0.62], p<0.0001 for the 0-2 scores and 
HR 0.78, [95%CI: 0.74-0.82], p<0.0001 for the 3-4 scores compared to scores >5. 
 
Cancer subtype analyses 
Further examining the same association analysis within sub-populations of distinct types 
of malignancies (figure 1), we found similar pattern on most cancers but melanoma. 
Among the breast cancer sample (n=10,407), above 80% AD adherence was associated 
with HR 0.81 [95%CI: 0.71–0.94] reduced mortality compared to the least adherent 
below 20%. Among the colon cancer sample (n=5,091) the highest adherence level of 
80% had a reduced risk of premature mortality versus the least adherent HR 0.82 
[95%CI: 0.71–0.95]. Among the lung cancer sample (n=1,183) the highest adherence 
level of 80% had a reduced risk of premature mortality versus the least adherent 0.79 
[95%CI: 0.64–0.98]. Among the prostate cancer subpopulation (n=2,960) the 80% 
adherence level had a reduced risk of premature mortality versus the least adherent 0.69 
[95%CI: 0.56–0.84]. In contrast, no relationship was observed between the highest 
adherent melanoma sample (n=2,056) versus the least adherent (HR 0.9 [95%CI: 0.67–
1.23, non-significant]). 





Analysis of sub-population with depression 
We further performed a complementary analysis of a sub-population within the cohort 
that had a diagnosis of major depressive disorder (ICD10 codes: F.32-F.33), malignancy 
and were AD users (n=14,349). Across the whole group, during the follow-up period 
2,938 (18.1%) patients died. Using the same survival model described above, similar 
results were found: HRs for mortality were 0.79 [95% CI: 0.69-0.9], 0.71 [95% CI: 0.64-
0.8] and 0.68 [95% CI: 0.62-0.75] for poor, moderate and good adherence levels, 
respectively, in comparison to the non-adherence group. Variations in mortality were 
noted and there was consistent reduced mortality across all adherence groups for lung, 
prostate and breast cancer (see table 3).  However, there was no evidence of an 
association between AD adherence and melanoma and colon cancer. 
Analysis of “new users for AD” 
About a third of the population entered the study with prescribed AD (“old users”) and 
67.5% (n=37,327) were prescribed AD for the first time during the study period, that is,  
a post cancer diagnosis (“new users”). Performing the same Hazard survival model for  
“new users” as a covariate revealed the same findings. HRs for mortality were 0.89 [95% 
CI: 0.83-0.96], 0.78 [95% CI: 0.73-0.84] and 0.72 [95% CI: 0.77-0.87] for poor, 








The novel finding of our large population-based cohort study of patients with 
cancer treated by AD (N=42075) is that greater adherence to AD was associated with 
decreased risk of all-cause mortality during the 4-year follow-up period after adjusting 
for the relevant confounding risk factors for mortality including age, gender, socio-
economic status, smoking status and physical comorbidities. We observed a similar 
relationship when we stratified the results according to the type of cancer including 
breast, colon, lung and prostate cancers, but not for melanoma patients. Interestingly, 
when we restricted our analysis to those with MDD and any type of cancer, there was 
evidence of reduced mortality in all AD groups. However, subgrouping for cancer type in 
those with MDD revealed that mortality was constantly reduced in all AD groups for 
lung, prostate and breast cancer, but not in any of the melanoma and colon cancer groups 
with MDD.  
In the presence of the few and inconsistent reports of the relationship between AD 
use and premature mortality (Chubak et al., 2008; Stockler et al., 2007; Walker et al., 
2012; Wernli et al., 2011), our finding utilizing a larger sample than all previous studies 
combined is important. In addition, our calculation of patient adherence may more 
accurately reflect the actual consumption of AD along the period they are prescribed, 
compared to previous studies which only considered if AD were used as a binary variable 
(Bambauer et al., 2006; Sawada et al., 2009; World Health Organization, 2003).  
Our findings contradict the pharmacoepidemiological report in a sample of 3,058 
breast cancer patients (Wernli et al., 2011), suggesting AD use may be associated with 
1.5-fold increased all-cause mortality. However, that study was based on patients' reports 
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via mail and was therefore subject to substantial recall and selection biases. In addition, it 
is limited by examining AD use and not adherence. Our data is in partial agreement with 
the report of 17,883 colorectal cancer or glioma patients(Walker et al., 2012) which 
observed no effect of TCA use on patient mortality, as when we restricted our sample to 
only those with MDD and colon cancer we found no evidence of the impact of AD 
adherence on mortality. However, that study was limited by substantial missing data with 
respect to major confounding factors such as smoking and obesity. Moreover, focusing 
only on TCA, representing a small portion of AD, is not generalizable to more commonly 
prescribed medications. Finally, no effect of AD on mortality was also reported in a 
sample of 1,306 women with breast cancer (Chubak et al., 2008). However, the authors 
were concerned by some key unmeasured variables, including potentially misclassified 
data. Furthermore, similarly to all previous reports, the evaluation of AD use as a binary 
variable is a major limitation.  
Our findings not only indicate that adherence to AD is associated with increased  
survival in patients with cancer, but that this relationship may be to some extent 
continuous, that is, even partial adherence to AD may be beneficial in terms of survival. 
However, the better survival of the low adherence group vs. none adherence, and the 
moderate adherence group vs. the low adherence did not repeat itself when comparing the 
high adherence vs. moderate adherence groups, indicating a possible ceiling effect of the 
benefit of AD adherence in terms of ameliorating survival. In addition, we observed some 
suggestion of cancer type specific variations in terms of mortality risk in those with 
MDD.        
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Surprisingly, the relationship between AD adherence and survival in the cohort, 
that was similarly observed in the breast, colon, prostate and lung cancer patients, did not 
repeat in the melanoma subgroup. Only scarce mixed pre-clinical data are available 
regarding a possible effect of AD on melanoma tumors. Whereas some studies suggested 
that certain ADs may be effective in inhibiting tumor growth in a murine model, have an 
in-vitro cytotoxic activity against human melanoma cells or possess antioxidant activity 
in mice, other studies indicated that SSRIs may increase mice brain metastases or not 
affect them (Boia-Ferreira et al.,  2017; Herr, Mohile, van, Brown, & Rich, 2016). To the 
best of our knowledge, no clinical studies evaluated this question, which is particularly 
intriguing since melanocyes originate from the embryonic ectoderm, similarly to the 
central nervous system. 
Similarly to our previous reports on mortality in other AD-using populations 
(Krivoy et al., 2015; Krivoy et al., 2016; Krivoy et al., 2017; Shoval et al., 2017), our 
unadjusted analyses in the present study showed increased rate of death in the higher 
adherence levels. As previously discussed broadly in these publications, we attribute this 
finding mainly to a more drug adherent behavior in the older and highly co-morbid 
patients, therefore such findings demonstrates the importance of having the capability to 
adjust for importance confounders.   
Whilst our data addresses an important gap within the literature, the findings 
should be interpreted in light of its limitations. The primary analyses did not include data 
regarding the indication as mental health diagnosis data in the database was incomplete. 
Additionally, data on causes of death was also not available, and thus we were unable to 
discriminate between death due to cancer, suicide and other causes. However, we 
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considered all-cause mortality a preferable outcome measure to evaluate the long-term 
global impact of AD adherence on cancer patients’ survival. Finally, though we used a 
reliable indicator for co-morbid physical conditions of the patients, there might be still 
residual confounding by unmeasured variables, such as grading and staging of the 
neoplasm.   
In conclusion, the present four-year follow-up study is the first to demonstrate the 
inverse association between adherence to AD and all-cause mortality in a general 
population-based large cohort of patients with cancer. This relationship is systematically 
repeated in all subtypes of cancer we studied, except for melanoma. Similarly to our 
previous studies in the general population and in certain other major physical disorders 
(Krivoy et al., 2015; Krivoy et al., 2016; Krivoy et al., 2017; Shoval et al., 2017), the 
beneficial effect of adherence to AD may be at least equally important in the high-risk 
population of patients with cancer. Psychiatrists, Oncologists and primary-care 
physicians should step up their efforts to sustain and enhance their patients' adherence to 
AD, as it may be associated with increased life-expectancy.   
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Table 1: Total patient population with cancer (N=42075) characteristics and mortality 
rates across demographic and clinical covariates. 
 
  Population  Mortality  
  n % n % 
Total  42075  8194 19 
Males  14864 35.3 3791 25.5 
Females  27211 64.7 4403 16.2 
Age at study entry 0-17 71 0.2 7 9.9 
 18-24 121 0.3 4 3.3 
25-39 1065 2.5 73 6.9 
40-64 13005 30.9 1354 10.4 
 65-74 10099 24.0 1563 15.5 
 75-84 13089 31.1 3240 24.8 
 >85 4625 11.0 1953 42.2 
Native  37230 88.5 7290 19.6 
Immigrant  4845 11.5 904 18.7 
Socio-economic status Low 13402 31.9 2333 17.4 
Moderate 17836 42.4 3649 20.5 
High 12701 30.2 2196 17.3 
CCI 0-2 13858 32.9 2316 16.7 
3-4 16774 39.9 2588 15.4 
>5 11418 27.1 3285 28.8 
Smoking status Never 29374 69.8 5613 19.1 
Past or Current 12220 29.0 2381 19.5 
Breast cancer  10407  1333 10 
Colon cancer  5091  1140 17 
Lung cancer  1183  561 31.1 
Prostate cancer  2960  608 15.4 
Melanoma  2056  287 10.7 




CCI – Charlson's Comorbidity Index 
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Table 2: Population characteristics across adherence levels (N=42075). Percentage 
represents proportions of variable across levels of adherence (row). 
 
 
* CCI – Charlson's Comorbidity Index 














    n  %   n %  N %   n %  
Gender Male 4289 29 2403 16 2608 18 5564 37 14864 
 Female 7803 29 4360 16 4760 17 10288 38 27211 
Age at study 
entry 
0-17 17 24 15 21 16 23 23 32 71 
18-24 37 31 20 17 22 18 42 35 121 
25-39 387 36 203 19 176 17 299 28 1065 
40-64 4508 35 2183 17 2186 17 4128 32 13005 
65-74 2912 29 1648 16 1765 17 3774 37 10099 
75-84 3227 25 2008 15 2323 18 5531 42 13089 




Low 4068 30 3679 27 1993 15 3662 27 13402 
Mod. 5319 30 2016 11 3269 18 7232 41 17836 
High 2680 21 3026 24 2077 16 4918 39 12701 
Smoking Never 8472 29 4717 16 5099 17 11086 38 29374 
 Ever 3499 29 1968 16 2190 18 4563 37 12220 
Immigrant No 10499 28 5874 16 6517 18 14340 39 37230 
 Yes 1593 33 889 18 851 18 1512 31 4845 
CCI* 0-2 3997 29 2271 16 2521 18 5069 37 13858 
 3-4 5004 30 2683 16 2911 17 6176 37 16774 
 >5 3078 27 1806 16 1933 17 4601 40 11418 
Mortality**  1970 16 1292 19 1458 20 3474 22 8194 
Total  12092  6763  7368  15852  42075 
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Table 3: Multivariate survival analysis of the effect of antidepressants’ adherence in sub-
population with diagnoses of depression and malignancy, by type of malignancy. Model 
is adjusted for age, sex, smoking status, socioeconomic status and Charslon’s 



















Melanoma 620 92 13.3 1.23 [0.63-2.37] 1.3 [0.62-2.75] 0.58 [0.21-1.57] 
Lung 367 161 36.3 0.52 [0.34-0.79] 0.56 [0.35-0.89] 0.45 [0.26-0.77] 
Prostate 915 223 21.4 0.44 [0.31-0.62] 0.4 [0.27-0.61] 0.5 [0.32-0.8] 
Colon 1746 402 20.1 0.8 [0.62-1.06] 0.73 [0.52-1.01] 0.89 [0.62-1.27] 
Breast 3574 497 12.5 0.66 [0.52-0.85] 0.69 [0.52-0.92] 0.69 [0.5-0.95] 
 









Figure 1: Relative hazard ratios (HR) for mortality by adherence level during 4 years 
follow-up (a, all malignancies, n=42075). Non-adherence level (<20%) serves as the 
reference. The model is based on Cox multivariate survival model adjusted for gender, 
age, smoking, socio-economic status and Charlson's comorbidity index. Each box (b-f) 
represents subpopulation with specific cancer type. 

